Mirikizumab for kids with ulcerative colitis or Crohn’s
Treatments studied
Part of Digestive system clinical trials.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a child who previously joined one of the listed mirikizumab studies and may benefit from more treatment
- You must have finished the prior study’s last visit and still be staying on mirikizumab
- If you are able to become pregnant, you must agree to pregnancy prevention (contraception) rules
- You must not have had serious safety problems or new issues that make restarting mirikizumab unsafe
- You must not have stopped the study medicine in the prior study in a way that would make restarting unsafe
- You cannot be pregnant or breastfeeding, and you must not have unreoved pre-cancer (adenomatous) colon polyps
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This trial tests a medication called Mirikizumab for adults over 60 with moderate to severe Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective for older adults with these conditions.
This study follows people with ulcerative colitis who are starting or have just started mirikizumab treatment. It aims to understand how well the drug works in real-world settings and how patients do over the next 12 months.
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
This study tests a combination of a drug called mirikizumab and a surgical procedure (curettage and closure) for people with Crohn's disease who have an active perianal fistula. The goal is to see if this treatment helps heal the fistula better than standard care.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.